In the backdrop of latest US tariffs on branded and patented medicines, the pharmaceutical manufacturers in Himachal Pradesh have asserted that it will not significantly impact their businesses as the industry largely produces generic medicines.

Highlighting the state’s robust pharma sector, Himachal’s industry leaders have downplayed the tariff’s effect on the production of generic medicines.

The tariff announced by US President Donald Trump will take effect from October 1 — the move that has triggered reactions from global pharmaceutical hubs.

The Vice-Chairman of Confederation of Indian Industry (CII Himachal) and Executive Director of Morepen Laboratories in Solan, Sanjay Suri, said, “More than 95 per cent of the pharmaceutical companies located in Baddi, Nalagarh, Kala Amb and Pa

See Full Page